Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Benjamin Willett

Physician Assistant, Medical Salem, OR Physician Assistant

NPI 1467722066 CMS profile 10576475

801 Mission St Se, Salem, OR 97302

Open in the dashboard

General payments

$10,544

245 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Benjamin Willett of Salem, OR is reported in the CMS Open Payments database as having received $10,544 across 245 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $7,761 138
2024 General $2,033 75
2023 General $531 21
2022 General $206 10
2021 General $13 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Benjamin Willett
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Benjamin Willett were reported at $7,761. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Benjamin Willett Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $13 $156 $41–$563 $132
2022 $206 $185 $55–$649 $149
2023 $531 $199 $58–$717 $160
2024 $2,033 $206 $62–$740 $164
2025 $7,761 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Genzyme Corporation $3,353 33 payments
  2. Regeneron Healthcare Solutions, Inc. $2,836 26 payments
  3. AstraZeneca Pharmaceuticals LP $710 25 payments
  4. GlaxoSmithKline, LLC. $587 34 payments
  5. Amgen Inc. $291 12 payments
  6. Takeda Pharmaceuticals U.S.A., Inc. $279 10 payments
  7. Merck Sharp & Dohme Corporation $272 12 payments
  8. United Therapeutics Corporation $241 12 payments
  9. AbbVie, Inc. $233 5 payments
  10. Insmed, Inc. $200 15 payments
  11. Other $1,541 61 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $5,935 237 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $2,352 2 payments
  3. Consulting Fee $2,016 2 payments
  4. Education $144 3 payments
  5. Travel and Lodging $97 1 payment
Products named General payments · program years 2021–2025
  1. DUPIXENT Immunology $5,681 41 payments
  2. DUPIXENT Immunology And Inflammation $2,717 21 payments
  3. FASENRA $424 10 payments
  4. TRELEGY ELLIPTA $334 19 payments
  5. TEZSPIRE $291 12 payments
  6. NUCALA $253 15 payments
  7. AIRSUPRA $192 6 payments
  8. Arikayce $187 14 payments
  9. Xolair $184 3 payments
  10. RINVOQ $180 3 payments
  11. Other $2,848 132 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

392

Median for Physician Assistant: 241

Drug cost

$73,320

Median for Physician Assistant: $4,110

Branded share of claims

54.6%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 64 $43,677
Breo Ellipta Fluticasone/Vilanterol Brand 13 $8,214
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 13 $6,975
Symbicort Budesonide/Formoterol Fumarate Brand 13 $3,332
Azelastine Hcl Generic 74 $2,422
Azelastine-Fluticasone Azelastine/Fluticasone Brand 17 $2,223
Fluticasone-Salmeterol Fluticasone Propion/Salmeterol Brand 13 $1,753
Albuterol Sulfate Hfa Albuterol Sulfate Brand 49 $1,460
Wixela Inhub Fluticasone Propion/Salmeterol Brand 19 $1,128
Ipratropium Bromide Generic 28 $704

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 16 billing codes

Paid by Medicare

$224,917

Of which drugs: $208,068

Medicare patients

74

Average age 73

Services billed

12,467

50 women, 24 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 62%
High blood pressure 55%
COPD 28%
Depression 27%
Osteoporosis 23%
Ischemic heart disease 22%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, tezepelumab-ekko, 1 mg J2356 Office 11 10,710 $152,791

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 32 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • GENZYME CORPORATION $352
  • Regeneron Healthcare Solutions, Inc. $82
$435 — —
TEZSPIRE
  • Amgen Inc. $168
  • AstraZeneca Pharmaceuticals LP $19
$187 — 10,710
FASENRA
  • AstraZeneca Pharmaceuticals LP $185
$185 — —
RINVOQ
  • AbbVie, Inc. $180
$180 — —
XOLAIR
  • Genentech USA, Inc. $164
  • Novartis Pharmaceuticals Corporation $16
$180 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 32 with Patron

Records

245 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Oregon

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record